Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine (“5-MeO-DMT”) organic synthesis scheme. This significant achievement marks a major breakthrough in the development of a suitable procedure for obtaining 5-MeO-DMT freebase as an Active Pharmaceutical Ingredient (“API”) with exceptionally high purity and pharmaceutical-grade quality.

5-MeO-DMT is a naturally occurring compound found in various plant and animal species, and it has garnered significant attention within the scientific and medical communities for its potential therapeutic properties. Biomind’s groundbreaking achievement opens the door to new possibilities in drug development and medical research.

Key accomplishments of the first 5-MeO-DMT organic synthesis scheme include:

  • Organic Synthesis Success: A pioneering organic synthesis scheme that enables the efficient production of 5-MeO-DMT freebase. This novel process ensures high purity and maintains the compound’s integrity, making it suitable for pharmaceutical applications.
  • Pharmaceutical-Grade Quality: The 5-MeO-DMT freebase produced using this new method and under Good Manufacturing Practices (GMP) meets stringent pharmaceutical standards, guaranteeing its suitability for use in the development of advanced medicines and therapies.
  • Potential Therapeutic Applications: The availability of high-purity 5-MeO-DMT as an API paves the way for innovative research and development in various therapeutic areas. Although Biomind primarily targets the treatment of mental health disorders, such as depression and anxiety, other areas of medicine could benefit from the availability of high-purity 5-MeO-DMT.
  • Commitment to Safety and Compliance: Biomind places an emphasis on safety and compliance with regulatory standards. The Company has undertaken rigorous testing and quality control measures to ensure the highest levels of product safety and consistency.

“Reaching this significant achievement enables us to guarantee the accessibility and cost-effectiveness of our innovative tryptamine-based formulations when they are ready for market release. At present, navigating the landscape of tryptamine-based products presents numerous challenges, including locating suppliers capable of meeting the stringent commercial and quality criteria necessary for pharmaceutical-grade products. Additionally, the associated complexities in the authorization process, substantial expenses, and intricate logistics further compound these challenges. By possessing the capacity to manufacture our own APIs while adhering to pharmaceutical-grade quality standards, we significantly mitigate the risk of supply shortages, positioning ourselves as an ideal partner within the traditional pharmaceutical sector”, commented Alejandro Antalich, CEO of Biomind Labs.

About Biomind Labs Inc.

Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-dimethyltryptamine (“DMT”), 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to provide patients access to affordable and modern-day treatments.